These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20945090)

  • 1. The benefits of discussing adjuvant therapies one at a time instead of all at once.
    Zikmund-Fisher BJ; Angott AM; Ubel PA
    Breast Cancer Res Treat; 2011 Aug; 129(1):79-87. PubMed ID: 20945090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A demonstration of ''less can be more'' in risk graphics.
    Zikmund-Fisher BJ; Fagerlin A; Ubel PA
    Med Decis Making; 2010; 30(6):661-71. PubMed ID: 20375419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving understanding of adjuvant therapy options by using simpler risk graphics.
    Zikmund-Fisher BJ; Fagerlin A; Ubel PA
    Cancer; 2008 Dec; 113(12):3382-90. PubMed ID: 19012353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer.
    Partridge AH; Sepucha K; O'Neill A; Miller KD; Motley C; Swaby RF; Schneider BP; Dang CT; Northfelt DW; Sledge GW
    JAMA Oncol; 2015 Jun; 1(3):369-74. PubMed ID: 26114161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Offering a choice between two adjuvant chemotherapy regimens: a pilot study to develop a decision aid for women with breast cancer.
    Irwin E; Arnold A; Whelan TJ; Reyno LM; Cranton P
    Patient Educ Couns; 1999 Jul; 37(3):283-91. PubMed ID: 14528554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
    Albain KS; Paik S; van't Veer L
    Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decision-making for patients with resectable breast cancer: individualized decisions for and by patients and their physicians.
    Loprinzi CL; Ravdin PM
    J Natl Compr Canc Netw; 2003 Apr; 1(2):189-96. PubMed ID: 19768877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
    Lancet; 2005 May 14-20; 365(9472):1687-717. PubMed ID: 15894097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Information for decision making by post-menopausal women with hormone receptor positive early-stage breast cancer considering adjuvant endocrine therapy.
    Feldman-Stewart D; Madarnas Y; Mates M; Tong C; Grunfeld E; Verma S; Carolan H; Brundage M
    Breast; 2013 Oct; 22(5):919-25. PubMed ID: 23721853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer.
    Paridaens RJ; Gelber S; Cole BF; Gelber RD; Thürlimann B; Price KN; Holmberg SB; Crivellari D; Coates AS; Goldhirsch A
    Breast Cancer Res Treat; 2010 Aug; 123(1):303-10. PubMed ID: 20195744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
    ; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
    J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlates of Adjuvant Therapy Attitudes in African American Breast Cancer Patients.
    Edmonds MC; Sutton AL; He J; Perera RA; Sheppard VB
    J Natl Med Assoc; 2020 Apr; 112(2):167-175. PubMed ID: 32197898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Present state and future prospects: a review of cooperative groups' adjuvant and neoadjuvant trials in breast cancer.
    Mamounas EP
    Clin Breast Cancer; 2001 Oct; 2 Suppl 1():S20-30. PubMed ID: 11970741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW; Henderson IC
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.